Use of vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, appears to lower all-cause mortality and all-cause hospitalizations at 1 year in patients with high-risk heart failure (HF) with reduced ejection fraction (HFrEF) and comorbid pulmonary hypertension (PH), as shown in a real-world study.
Previous trials (VICTORIA and VICTOR) have demonstrated the beneficial effects of vericiguat in the broader HFrEF population, but neither trial examined those with HFrEF and PH, according to study co-author Dr Ogheneakpobor Ubogun, Montefiore St Luke Cornwall, Newburgh, New York, US. [JACC Heart Fail 2018;6:96-104; Eur J Heart Fail 2025;27:209-218]
In this retrospective propensity score-matched (PSM) real-world analysis, treatment with vericiguat significantly correlated with a reduction in all-cause mortality at 1 year compared with no treatment (21.9 percent vs 27.2 percent; risk ratio [RR], 0.806, 95 percent confidence interval [CI], 0.657‒0.990; risk difference [RD], ‒5.3 percent, 95 percent CI, ‒10.3 to ‒0.3; p=0.039). [AHA 2026, abstract 6968]
“While the hazard ratio [HR] trended toward benefit (HR, 0.805, 95 percent CI, 0.636-1.019), it did not reach significance on the survival analysis (p=0.249), suggesting this effect is related to the small matched sample (n=570),” Ubogun said.
Hospitalizations
Similarly, patients treated with vericiguat had a 30-percent lower risk of all-cause hospitalization (53.7 percent vs 62.8 percent; RR, 0.855, 95 percent CI, 0.774‒0.944; HR, 0.694, 95 percent CI, 0.596‒0.809; p=0.002) and a longer median time to first hospitalization (210 vs 83 days) compared with those who did not receive treatment.
Notably, 3-point major adverse cardiovascular event (MACE), stroke, ventricular tachycardia/fibrillation, cardiac arrest, acute myocardial infraction (MI), and HF hospitalization did not significantly differ between groups. However, directional trends were consistently in favour of vericiguat across all arrhythmic and ischaemic endpoints.
“These findings extend the VICTORIA and VICTOR trial evidence to a comorbid PH population not specifically examined in prior randomized controlled trials and align with vericiguat's dual mechanism of action on both myocardial and pulmonary vascular cyclic GMP signalling,” Ubogun said.
Study details
Ubogun and colleagues used the TriNetX US Collaborative Network to conduct this retrospective PSM cohort study. They identified a total of 575 patients aged ≥18 years with HFrEF and PH who were treated with vericiguat and 235,652 patients who did not receive vericiguat. PSM (1:1), which was performed to balance demographics, comorbidities, and concomitant medications, yielded 570 matched pairs.
All-cause mortality served as the primary outcome, while 3-point MACE, atrioventricular block, all-cause hospitalization, stroke, HF hospitalization, acute MI, cardiac arrest, and percutaneous coronary intervention were secondary outcomes. Finally, Kaplan-Meier and Cox analyses were used to estimate RR, RD, and HR (p<0.05 defined statistical significance).
“Prospective studies specifically enrolling HFrEF plus PH patients are warranted,” Ubogun said.
“HFrEF and comorbid PH represents a high-risk phenotype in advanced cardiovascular disease, with marked mortality and hospitalization rates compared to HFrEF alone,” according to Ubogun and colleagues.